Other pre‐treatment biomarkers, including CD3+, CD8+, CD3 + CD4+, CD20+, CD68+ tumor‐associated macrophages (TAM), NK cells, and TLS, were not different between the TRG 1–3 and TRG 4–5 groups. This evidence concerns the gene CD68 and neoplasm.